Premium
α‐Interferon treatment for idiopathic hypereosinophilic syndrome
Author(s) -
Bockenstedt Paula L.,
Santinga John T.,
Bolling Steven F.
Publication year - 1994
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830450311
Subject(s) - hypereosinophilia , hypereosinophilic syndrome , medicine , prednisone , eosinophil , immunology , idiopathic pulmonary fibrosis , eosinophilia , pathology , gastroenterology , lung , asthma
Idiopathic hypereosinophilic syndrome (HES) is a poorly understood disorder characterized by a markedly elevated peripheral blood eosinophil count in the absence of known associated causes of hypereosinophilia. Idiopathic hypereosinophilic syndrome is associated with eosinophil‐induced organ damage, including endomyocardial and pulmonary fibrosis, stroke, and gastrointestinal disease. Treatment of idiopathic HES is centered on the reduction of peripheral circulating eosinophils in an effort to diminish tissue infiltration and destruction. Multiple cytotoxic agents have been tried, with variable resutts. Prednisone and hydroxyurea have remained the therapies of choice in long term treatment of idiopathic HES. We report here the successful 2 year treatment of aggressive idiopathic HES, refractory to hyroxyurea and prednisone, with α‐interferon. © 1994 Wiley‐Liss, Inc.